New lineage of SARS-CoV-2 detected in Canadian deer
An investigation led by Canadian Food Inspection Agency scientists has identified a new and highly divergent lineage of SARS-CoV-2, the virus that causes COVID-19 in white-tailed deer (WTD) in that country. The findings, which are not peer-reviewed, are published as a preprint study on bioRxiv.
The divergent strain was seen in samples from Ontario deer that were collected from Nov 1 to Dec 31, 2021, during the annual hunting season. The researchers collected 213 nasal swabs and tissue from 294 retropharyngeal lymph nodes. Overall, the authors said, SARS-CoV-2 RNA was detected in 21 samples representing 6% (17/298) of hunter-harvested deer. All positive deer from were from southwestern Ontario.
Using nasal swab samples, the researchers produced 5 high-quality genomes and 3 partial genomes of the virus, and they identified a highly divergent strain that most closely resembled sequences seen in human and mink samples from Michigan collected in September and October 2020; southwestern Ontario borders Michigan.
"This high degree of divergence (and consequent long branch in the phylogenetic analyses) is indicative of a period of unsampled viral evolution leading to 49 mutations compared to the closest genomes," the authors said. "This is reminiscent of the long branch and viral evolution that led to the Omicron variant, which has recently been linked to a possible mouse reservoir."
The authors say there was no evidence of animal-to-human spillover with this strain but say it could be possible.
"At this time, there is no evidence of recurrent deer to human or sustained human to human transmission of the Ontario WTD SARS-CoV-2 clade," the authors wrote. "However, the emergence of Omicron and the end of deer hunting season has meant both human and WTD testing and genomic surveillance in this region has been limited since these samples were collected."
Interspecies spillover has been a growing concern among researchers around the world, and has been documented in mink and deer in North America.
Feb 25 bioRxiv study
Trial finds azithromycin does not reduce post-RSV wheezing in kids
A randomized trial conducted among infants with severe respiratory syncytial virus (RSV) bronchiolitis found that administration of azithromycin did not prevent future wheezing, researchers reported yesterday in The New England Journal of Medicine–Evidence.
For the double-blind, placebo-controlled trial, a team led by researchers from Washington University School of Medicine in St. Louis and Vanderbilt University enrolled 200 otherwise healthy 1- to 18-month-old children hospitalized with RSV bronchiolitis, which is a well-known risk factor for the development of childhood asthma. The infants were randomized 1:1 to receive either oral azithromycin—which the researchers hypothesized might attenuate airway inflammation during RSV bronchiolitis—or placebo for 14 days. The primary outcome was the occurrence of recurrent wheeze over the following 2 to 4 years.
A total of 188 infants (96 in the azithromycin group and 92 in the placebo group) had at least one follow-up visit. While children who received azithromycin had lower levels of interleukin 8 (a marker of airway inflammation) compared with those who received placebo, azithromycin did not reduce the risk of post-RSV recurrent wheeze. Forty-five percent of children in the azithromycin group developed recurrent wheeze, compared with 37% in the placebo group (adjusted hazard ratio, 1.45; 95% confidence interval [CI], 0.92 to 2.29; P = 0.11).
Azithromycin also did not reduce the risk of recurrent wheeze among infants already receiving other antibiotic treatment at the time of enrollment (44.8% in the azithromycin group vs 46.2% in the placebo group; hazard ratio, 0.94; 95% CI, 0.43 to 2.07). In contrast, among antibiotic-naïve participants (133), azithromycin therapy resulted in a risk of subsequent recurrent wheeze compared with placebo (47.8% vs 31.8%; hazard ratio, 1.79; 95% CI, 1.03 to 3.10).
"In conclusion, azithromycin therapy during early-life acute severe RSV bronchiolitis did not reduce recurrent wheeze occurrence over the following 2 to 4 years," the study authors wrote. "Our findings are consistent with national bronchiolitis guidelines, which recommend against the use of antibiotics during acute bronchiolitis because of a lack of effect on the acute illness, and they extend this recommendation by demonstrating the lack of a salutary effect on recurrent wheeze."
Feb 27 N Engl J Med Evidence study